ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma announced the allowance of a US patent application covering arginine deiminase (ADI) encapsulated into red blood cells for the treatment of arginase-1 deficiency (A1D), a debilitating rare metabolic disease

Menu